Societal impacts of treatment of early breast cancer: implications for future research, policy and practice
Jun 11, 2019
RAND Europe conducted a study on the societal impact of early breast cancer. This study was divided into three interconnected phases, the first being. a mapping review on the published literature on the impacts of treatment of early breast cancer, which revealed existing gaps in the evidence on the non-clinical impacts of treatment of early breast cancer. This study aims to enrich the evidence base on the broader impacts of early breast cancer.
Implications for future research, policy and practice
|PDF file||0.9 MB||
Use Adobe Acrobat Reader version 10 or higher for the best experience.
RAND Europe conducted a study on the societal impact of early breast cancer. This study was divided into three interconnected phases, which together aim to enrich the evidence base on the broader health, societal and economic impacts of treatment of early breast cancer, using a mixed methods approach. It highlights the available evidence and state of research on early breast cancer and considers the impact and 'cost' of disease progression for patients and their carers, as well as wider society. The first phase consisted of a mapping review on the published literature on the impacts of treatment of early breast cancer. The review revealed existing gaps in the evidence on the non-clinical impacts of treatment of early breast cancer to patients, carers or wider society. Studies of treatment effectiveness clearly dominate the literature and there is much less evidence on other types of outcomes extending beyond traditional treatment effectiveness evaluations. Yet understanding the wider impacts of cancer survivorship is important to better understand the impacts beyond treatment of breast cancer, and there is a need for more detailed analyses of these to inform better-informed decision making.
Eligibility criteria and developing search terms
Final search sequence for the mapping review
The research described in this report was sponsored by F. Hoffmann-La Roche Ltd and conducted by RAND Europe.
This report is part of the RAND Corporation Research report series. RAND reports present research findings and objective analysis that address the challenges facing the public and private sectors. All RAND reports undergo rigorous peer review to ensure high standards for research quality and objectivity.
This document and trademark(s) contained herein are protected by law. This representation of RAND intellectual property is provided for noncommercial use only. Unauthorized posting of this publication online is prohibited; linking directly to this product page is encouraged. Permission is required from RAND to reproduce, or reuse in another form, any of its research documents for commercial purposes. For information on reprint and reuse permissions, please visit www.rand.org/pubs/permissions.
The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.